innoscripta Stock Rebounds as Management Courts Shareholders Amid Tax Investigation

innoscripta stock jumps 13% to EUR 46.50 after a 52-week low on a tax probe; H1 revenue rose 43% as investors weigh legal risk.

Shares of innoscripta SE climbed 13 percent on Monday to EUR 46.50, extending a recovery that began after the stock touched a 52-week low of EUR 31.05 in the wake of a heavy sell-off. The earlier slump was triggered by authorities raiding company premises as part of a tax investigation, a development that rattled market confidence and sparked aggressive selling.

The bounce marks a sharp reversal in sentiment, though investors now face a fundamental question: does this signal the start of a durable bottoming-out, or merely a brief rally in a deeply uncertain environment? With the stock having shed substantial value in recent sessions, every fresh detail about the company's actual operating condition carries outsized weight.

The Investigation and Its Uncertain Reach

At the heart of the matter is a suspicion that innoscripta helped clients obtain unjustified tax benefits tied to research grants. Searches were conducted at group locations in Munich and Tutzing. For shareholders, the critical issue is whether these are isolated lapses or whether the advisory model itself contains systemic weaknesses.

Management has stressed in mandatory disclosures that, based on preliminary findings, the issues appear limited to misconduct by individual employees on specific mandates. The company also stated that no business transactions from the current fiscal year are affected by the investigation. At the same time, innoscripta acknowledged that a conclusive financial assessment of potential consequences is not yet possible. Until investigators give the all-clear, the financial scope of any back-payments or procedural risks remains open—and that legal uncertainty is the pivot on which the share price turns.

A Business Case Built on Growth

The invitation to shareholders and the emphasis on operating momentum come during a challenging period. In an interview on September 28, CFO Alexander Meyer and COO Sebastian Schwertlein detailed the company's operating progress, international expansion, and system development. The leadership team reported strong gains for the first six months: revenue growth of 43 percent in the first half of 2026, with earnings before interest and taxes up 49 percent over the same period. Beyond the financial metrics, Meyer and Schwertlein highlighted the software company's international advances.

The upcoming product presentation will focus on innoscripta's proprietary software systems, whose continuous development—alongside entry into new markets—forms a central pillar of the company's activities. By hosting shareholders at its Tutzing headquarters, the company is seeking direct dialogue with investors, with specific dates for the meetings to be announced at short notice.

Two Paths Ahead

In the optimistic scenario, innoscripta succeeds in fully insulating its operating business from the tax allegations. Management has already assured that day-to-day operations are intact and continuing without restriction, while signaling full transparency and comprehensive cooperation with authorities to clarify the matter. Should this transparency push gain traction and the company demonstrate that the allegations are indeed confined to individual employees, market nervousness could dissipate quickly. In that case, the heavily discounted share price would offer room for a meaningful re-rating, since the core operating business would remain untouched.

Against that stands a serious downside risk, driven primarily by potential reputational damage. When assisting with research grants, corporate clients rely on absolute legal reliability and regulatory compliance. If the investigation uncovers broader deficiencies in control mechanisms or even structural violations, the service provider faces a painful loss of trust among existing and prospective clients. Such erosion could lead to cancelled mandates or a drought of lucrative new orders. Add to that the burden of lengthy proceedings that tie up significant management capacity. Should financial liabilities from the investigation materialize down the road, the earnings base would come under sustained pressure—and the recent gains would quickly evaporate.

What to Watch

For the stock's next move, clear markers matter. As long as the shares hold above the recent 52-week low of EUR 31.05, the chance of stabilization remains intact. If that support breaks on fresh regulatory steps or confirmation of wider irregularities, an immediate continuation of the prior decline looms.

The next concrete catalyst is the announced product presentation for shareholders, where management will seek direct engagement with the capital markets. Future interim reports and official updates on the investigation's progress should prove equally telling. Before committing new capital, investors would be wise to wait for solid evidence of a lasting operational separation from the legal issues.